What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database - Archive ouverte HAL Access content directly
Journal Articles Expert Opinion on Drug Safety Year : 2021

What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database

(1) , (1) , , , , , (1) , (1) , (1)
1

Abstract

The inherent risk of agranulocytosis associated with clozapine requires the realization of weekly white blood cell monitoring (WBCM) during the 18 first weeks of treatment. The aim of this study was to assess the compliance with WBCM during clozapine initiation for schizophrenia and Parkinson's disease (PD) subjects.
Not file

Dates and versions

hal-03406940 , version 1 (28-10-2021)

Identifiers

Cite

Edouard-Jules Laforgue, Marion Istvan, Marylène Guerlais, Anicet Chaslerie, Pascal Artarit, et al.. What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database: A compliance analysis using the French health insurance database. Expert Opinion on Drug Safety, 2021, 20 (10), pp.1247-1256. ⟨10.1080/14740338.2021.1939304⟩. ⟨hal-03406940⟩
19 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More